“Further analyses of clinical effectiveness are being conducted for those EPP patients who continue treatment and those who received their first treatment after 30 June 2017”
Hmmm....I hope this “Further analyses” of post 30 June data is not needed to finalise the FDA Submission.
Otherwise i’d expect further delays on that of at least 2 - 3 months.
- Forums
- ASX - By Stock
- Ann: CLINUVEL hosts European EPP Expert Meeting
“Further analyses of clinical effectiveness are being conducted...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
|
|||||
Last
$13.96 |
Change
-0.200(1.41%) |
Mkt cap ! $699.0M |
Open | High | Low | Value | Volume |
$14.20 | $14.24 | $13.88 | $631.9K | 44.90K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 416 | $13.96 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.04 | 192 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 416 | 13.960 |
1 | 1435 | 13.920 |
2 | 262 | 13.880 |
1 | 192 | 13.860 |
1 | 192 | 13.830 |
Price($) | Vol. | No. |
---|---|---|
14.040 | 192 | 1 |
14.060 | 192 | 1 |
14.070 | 200 | 1 |
14.090 | 192 | 1 |
14.100 | 600 | 1 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online